Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Meridian Bioscience has entered into a partnership agreement with the performance & life science chemicals division of Merck KGaA and its American company, EMD, focused on the development of new assays for the clinical market.
Subscribe to our email newsletter
The first product from this long-term partnership is scheduled to launch in the US market during the first half of Meridian’s fiscal 2007. In addition to providing Meridian with new products in the short-term, the partnership is also expected to enhance Meridian’s new product pipeline for the microbiology laboratory and contribute sales growth over the next few years.
“This partnership demonstrates Meridian’s dedication to organic growth through innovation that maximizes internal and external R&D efforts,” said John Kraeutler, president and COO of Meridian. “By partnering with Merck, Meridian is well-positioned to also leverage external relationships that will generate additional growth.”
“We are excited about this partnership with Meridian Bioscience,” added Dr Andreas Rauh, VP of the laboratory business for Merck KGaA. “This partnership will allow for several of Merck’s high-quality products to reach markets that are not currently being accessed. In addition, future R&D projects with Meridian could further enhance the Merck portfolio of products.”